Semaglutide
FDA approved · RxGLP-1 receptor agonist
Also known as: Ozempic, Wegovy, Rybelsus
FDA approved and prescription only. Sold as Ozempic (type 2 diabetes) and Wegovy (weight management).
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 790 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven in large human trials: about 15% average weight loss, strong blood-sugar control, and reduced cardiovascular events. This is one of the best-evidenced compounds in this library.
What it is
Mimics the GLP-1 hormone: it increases insulin secretion when blood sugar is high, slows stomach emptying, and reduces appetite.
What the research says
The STEP Phase 3 trials showed roughly 15% average body-weight reduction.
Approved on the SUSTAIN trial program.
The SELECT trial showed reduced major cardiovascular events in certain populations.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Semaglutide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Semaglutide is the intervention being tested.
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Phase and status counts reflect the 100 most recent studies; the registered total above is exact.
FDA recalls & enforcement
Live from openFDA. Times the FDA required a Semaglutide product to be pulled from the market, with the stated reason. A recall is a specific batch or manufacturing action, not a verdict on the compound itself.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalled by Cardinal Health Inc.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Common GI side effects: nausea, vomiting, constipation, especially while escalating the dose.
- Muscle loss can occur without adequate protein and resistance training.
- Illegal research and counterfeit versions are widespread and have prompted FDA and EMA warnings.
- It is a prescription medicine. Use outside medical supervision is unsafe and unlawful.
Doses reported in studies & protocols
Approved schedules escalate slowly (for example starting at 0.25 mg and stepping up over months under a prescriber). Follow a clinician, not a forum. This is not a recommendation.
Purity reality
A top counterfeit target. Only pharmacy-dispensed product has a verified supply chain.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.